Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Washington

Peptide legality · Washington · updated 2026-09-21

Are peptides legal in Washington?

Restricted

In Washington, peptides are restricted: brand-name GLP-1 medicines are legal by prescription, but the state has issued specific compounding guidance and has actively enforced it, and standalone research peptides remain unapproved.

Legal status overview

Washington restricts peptides more actively than most states, so brand-name GLP-1 medicines are legal by prescription while compounded and research peptides face specific rules and enforcement. The Washington Medical Commission issued a semaglutide compounding statement, and the Pharmacy Quality Assurance Commission has imposed a stop-service order on a GLP-1 sterile compounder. Compounded semaglutide is allowed only under narrow federal grounds and must use pharmaceutical-grade base (no salt forms), with a valid certificate of analysis, sourced from an FDA-registered establishment licensed in Washington. Research peptides such as BPC-157 and TB-500 are unscheduled but not FDA-approved. This is information, not medical or legal advice.

Key points

  • The Washington Medical Commission adopted a semaglutide compounding statement (approved August 22, 2024) limiting compounding to the narrow grounds allowed under the federal Food, Drug, and Cosmetic Act. [1]
  • Washington requires that only semaglutide base be compounded; salt forms such as sodium or acetate are prohibited because they lack federal support and safety data. [1]
  • Any active ingredient must be pharmaceutical grade (not 'research use only'), carry a valid certificate of analysis, and come from an FDA-registered establishment licensed in Washington. [1]
  • The Pharmacy Quality Assurance Commission has demonstrated enforcement by issuing a stop-service order against a GLP-1 sterile compounder for compounding and licensure failures. [4]
  • Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA, and routine copies narrowed after the shortage was declared resolved in February 2025. [2]
  • BPC-157 is not a controlled substance and was removed from FDA Category 2 in April 2026, but it is not FDA-approved and not yet permitted for compounding pending final rulemaking. [5]
  • Noncompliance can trigger disciplinary action under Washington statutes RCW 18.64.026 and RCW 18.130.180. [1]

Compound-by-compound status

BPC-157
Gray area
Not a controlled substance and not FDA-approved; removed from 503A Category 2 in April 2026 and recommended for 503A in July 2026, but not yet permitted for compounding pending final FDA rulemaking.
GLP-1 class: Wegovy® (semaglutide) and Zepbound® (tirzepatide)
Restricted
Branded products are FDA-approved and legal by prescription; compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA, and Washington permits only the base form from an FDA-registered, state-licensed source with a certificate of analysis.
TB-500 (thymosin beta-4 fragment)
Restricted
Not FDA-approved and not on the permitted 503A bulk substances list; 'research use only' material is barred from compounding under Washington sourcing rules.
Growth hormone / somatropin
Restricted
FDA-approved by prescription for defined indications; federal law (21 U.S.C. 333(e)) makes distribution for non-approved uses a crime, so access is tightly restricted.

Frequently asked questions

Is compounded semaglutide legal in Washington?

It is allowed only under narrow federal grounds, must use pharmaceutical-grade semaglutide base (no salt forms) from an FDA-registered, Washington-licensed source, and must carry a certificate of analysis. Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA.

Has Washington enforced its peptide and GLP-1 rules?

Yes. The Pharmacy Quality Assurance Commission has issued a stop-service order against a GLP-1 sterile compounder, and noncompliance can lead to discipline under RCW 18.64.026 and RCW 18.130.180.

Is BPC-157 legal in Washington?

BPC-157 is not a controlled substance, but it is not FDA-approved and is not currently permitted for pharmacy compounding, so it stays in a gray zone. Research-use-only material cannot be used in compounding under Washington rules.

Why can Washington bar salt forms of semaglutide?

Salt forms such as sodium or acetate do not meet the federal bulk-substance requirements and lack safety and effectiveness data, so Washington permits only the base form used in the branded products.

Are brand-name GLP-1 drugs legal in Washington?

Yes. Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA-approved and legally prescribed; the restrictions target compounded and research peptides.

General information based on the sourced research above, not legal advice. For a specific situation in Washington, consult a licensed attorney familiar with pharmaceutical law.